Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Follicular Lymphoma – Pipeline Review, H2 2016, provides an overview of the Follicular Lymphoma (Oncology) pipeline landscape.
Follicular lymphoma is a common type of non-Hodgkin Lymphoma (NHL). It is a slow-growing lymphoma that arises from B-cells, a type of white blood cell. It is also called an "indolent" or "low-grade" lymphoma for its slow nature. Follicular lymphoma mainly affects older adults. Enlargement of lymph nodes is a common symptom. Fever, weight loss, sweating and fatigue are other symptoms of lymphoma. There are different types of treatment for patients with follicular lymphoma such as surgery, radiation therapy, and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Follicular Lymphoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Follicular Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Follicular Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Follicular Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 10, 46, 29, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 1 molecules, respectively.Follicular Lymphoma.
Follicular Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Follicular Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Follicular Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Follicular Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Follicular Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Follicular Lymphoma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Follicular Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Follicular Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AbbVie Inc
Affimed GmbH
Amgen Inc
Asana BioSciences LLC
Bayer AG
BeiGene Ltd
Bio-Path Holdings Inc
Biocon Ltd
Biogen Inc
Biogenomics Limited
Biothera Pharmaceutical Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corp
Celldex Therapeutics Inc
Celltrion Inc
Cellular Biomedicine Group Inc
Coherus BioSciences Inc
Constellation Pharmaceuticals Inc
CSPC Pharmaceutical Group Limited
CTI BioPharma Corp
Curis Inc
Dynavax Technologies Corp
Eisai Co Ltd
EpiZyme Inc
F. Hoffmann-La Roche Ltd
Genentech Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Hutchison MediPharma Ltd
Immune Design Corp
ImmunoGen Inc
Immunomedics Inc
Johnson & Johnson
Juno Therapeutics Inc
Karyopharm Therapeutics Inc
Kite Pharma Inc
MedImmune LLC
Medivation Inc
MEI Pharma Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
MorphoSys AG
Nordic Nanovector ASA
Novartis AG
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pharmacyclics Inc
Portola Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
Sandoz International GmbH
Seattle Genetics Inc
Takeda Pharmaceutical Company Ltd
TG Therapeutics Inc
Verastem Inc
'
Table of Contents
Table of Contents 2
Introduction 6
Follicular Lymphoma Overview 7
Therapeutics Development 8
Follicular Lymphoma - Therapeutics under Development by Companies 10
Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes 15
Follicular Lymphoma - Pipeline Products Glance 16
Follicular Lymphoma - Products under Development by Companies 19
Follicular Lymphoma - Products under Investigation by Universities/Institutes 25
Follicular Lymphoma - Companies Involved in Therapeutics Development 26
Follicular Lymphoma - Therapeutics Assessment 83
Drug Profiles 97
Follicular Lymphoma - Dormant Projects 507
Follicular Lymphoma - Discontinued Products 510
Follicular Lymphoma - Product Development Milestones 511
Appendix 528
List of Tables
Number of Products under Development for Follicular Lymphoma, H2 2016 19
Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 22
Number of Products under Development by Companies, H2 2016 (Contd..1) 23
Number of Products under Development by Companies, H2 2016 (Contd..2) 24
Number of Products under Development by Companies, H2 2016 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H2 2016 26
Comparative Analysis by Late Stage Development, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 28
Comparative Analysis by Early Stage Development, H2 2016 29
Products under Development by Companies, H2 2016 30
Products under Development by Companies, H2 2016 (Contd..1) 31
Products under Development by Companies, H2 2016 (Contd..2) 32
Products under Development by Companies, H2 2016 (Contd..3) 33
Products under Development by Companies, H2 2016 (Contd..4) 34
Products under Development by Companies, H2 2016 (Contd..5) 35
Products under Investigation by Universities/Institutes, H2 2016 36
Follicular Lymphoma - Pipeline by AbbVie Inc, H2 2016 37
Follicular Lymphoma - Pipeline by Affimed GmbH, H2 2016 38
Follicular Lymphoma - Pipeline by Amgen Inc, H2 2016 39
Follicular Lymphoma - Pipeline by Asana BioSciences LLC, H2 2016 40
Follicular Lymphoma - Pipeline by Bayer AG, H2 2016 41
Follicular Lymphoma - Pipeline by BeiGene Ltd, H2 2016 42
Follicular Lymphoma - Pipeline by Bio-Path Holdings Inc, H2 2016 43
Follicular Lymphoma - Pipeline by Biocon Ltd, H2 2016 44
Follicular Lymphoma - Pipeline by Biogen Inc, H2 2016 45
Follicular Lymphoma - Pipeline by Biogenomics Limited, H2 2016 46
Follicular Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H2 2016 47
Follicular Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 48
Follicular Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 49
Follicular Lymphoma - Pipeline by Celgene Corp, H2 2016 50
Follicular Lymphoma - Pipeline by Celldex Therapeutics Inc, H2 2016 51
Follicular Lymphoma - Pipeline by Celltrion Inc, H2 2016 52
Follicular Lymphoma - Pipeline by Cellular Biomedicine Group Inc, H2 2016 53
Follicular Lymphoma - Pipeline by Coherus BioSciences Inc, H2 2016 54
Follicular Lymphoma - Pipeline by Constellation Pharmaceuticals Inc, H2 2016 55
Follicular Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 56
Follicular Lymphoma - Pipeline by CTI BioPharma Corp, H2 2016 57
Follicular Lymphoma - Pipeline by Curis Inc, H2 2016 58
Follicular Lymphoma - Pipeline by Dynavax Technologies Corp, H2 2016 59
Follicular Lymphoma - Pipeline by Eisai Co Ltd, H2 2016 60
Follicular Lymphoma - Pipeline by EpiZyme Inc, H2 2016 61
Follicular Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 62
Follicular Lymphoma - Pipeline by Genentech Inc, H2 2016 63
Follicular Lymphoma - Pipeline by Gilead Sciences Inc, H2 2016 64
Follicular Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2016 65
Follicular Lymphoma - Pipeline by Hutchison MediPharma Ltd, H2 2016 66
Follicular Lymphoma - Pipeline by Immune Design Corp, H2 2016 67
Follicular Lymphoma - Pipeline by ImmunoGen Inc, H2 2016 68
Follicular Lymphoma - Pipeline by Immunomedics Inc, H2 2016 69
Follicular Lymphoma - Pipeline by Johnson & Johnson, H2 2016 70
Follicular Lymphoma - Pipeline by Juno Therapeutics Inc, H2 2016 71
Follicular Lymphoma - Pipeline by Karyopharm Therapeutics Inc, H2 2016 72
Follicular Lymphoma - Pipeline by Kite Pharma Inc, H2 2016 73
Follicular Lymphoma - Pipeline by MedImmune LLC, H2 2016 74
Follicular Lymphoma - Pipeline by Medivation Inc, H2 2016 75
Follicular Lymphoma - Pipeline by MEI Pharma Inc, H2 2016 76
Follicular Lymphoma - Pipeline by Merck & Co Inc, H2 2016 77
Follicular Lymphoma - Pipeline by Merck KGaA, H2 2016 78
Follicular Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 79
Follicular Lymphoma - Pipeline by Mirati Therapeutics Inc, H2 2016 80
Follicular Lymphoma - Pipeline by MorphoSys AG, H2 2016 81
Follicular Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2016 82
Follicular Lymphoma - Pipeline by Novartis AG, H2 2016 83
Follicular Lymphoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 84
Follicular Lymphoma - Pipeline by Pfizer Inc, H2 2016 85
Follicular Lymphoma - Pipeline by Pharmacyclics Inc, H2 2016 86
Follicular Lymphoma - Pipeline by Portola Pharmaceuticals Inc, H2 2016 87
Follicular Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H2 2016 88
Follicular Lymphoma - Pipeline by Sandoz International GmbH, H2 2016 89
Follicular Lymphoma - Pipeline by Seattle Genetics Inc, H2 2016 90
Follicular Lymphoma - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 91
Follicular Lymphoma - Pipeline by TG Therapeutics Inc, H2 2016 92
Follicular Lymphoma - Pipeline by Verastem Inc, H2 2016 93
Assessment by Monotherapy Products, H2 2016 94
Assessment by Combination Products, H2 2016 95
Number of Products by Stage and Target, H2 2016 97
Number of Products by Stage and Mechanism of Action, H2 2016 101
Number of Products by Stage and Route of Administration, H2 2016 105
Number of Products by Stage and Molecule Type, H2 2016 107
Follicular Lymphoma - Dormant Projects, H2 2016 518
Follicular Lymphoma - Dormant Projects (Contd..1), H2 2016 519
Follicular Lymphoma - Dormant Projects (Contd..2), H2 2016 520
Follicular Lymphoma - Discontinued Products, H2 2016 521
List of Figures
Number of Products under Development for Follicular Lymphoma, H2 2016 19
Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Investigation by Universities/Institutes, H2 2016 26
Comparative Analysis by Late Stage Development, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 28
Comparative Analysis by Early Stage Products, H2 2016 29
Assessment by Monotherapy Products, H2 2016 94
Number of Products by Top 10 Targets, H2 2016 96
Number of Products by Stage and Top 10 Targets, H2 2016 96
Number of Products by Top 10 Mechanism of Actions, H2 2016 100
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 100
Number of Products by Routes of Administration, H2 2016 104
Number of Products by Stage and Routes of Administration, H2 2016 104
Number of Products by Top 10 Molecule Types, H2 2016 106
Number of Products by Stage and Top 10 Molecule Types, H2 2016 106
